Pirtobrutinib (JAYPIRCA)
Bruton tyrosine kinase (BTK) inhibitor (non-covalent, targeted anticancer therapy)
Pirtobrutinib (JAYPIRCA)
Forms and strengths
Form: TabletStrength: 50 mg, 100 mg
References
Indication
- Pirtobrutinib is used as a single agent to treat adults with mantle cell lymphoma that has relapsed or is refractory after at least two prior lines of therapy, including a BTK inhibitor.
- Pirtobrutinib is used as a single agent to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
- Pirtobrutinib was authorized in Canada under a Notice of Compliance with Conditions, based on promising early evidence, pending results of trials to confirm its clinical benefit.
Pregnancy
- There are no adequate studies of pirtobrutinib in pregnant women, but animal studies show it can cause fetal harm, including reduced fetal weight, fetal death, and birth defects.
- Pirtobrutinib should not be used during pregnancy, and women of childbearing potential should have a pregnancy test before starting treatment.
- Women of childbearing potential should use highly effective contraception during treatment and for at least 5 weeks after the last dose; men with partners of childbearing potential should use effective contraception during treatment and for 3 months after the last dose.
Breastfeeding
- It is not known whether pirtobrutinib passes into human breast milk or affects milk production or the breastfed infant.
- Breastfeeding is not recommended during treatment and for one week after the last dose.
Geriatrics
- No overall difference in effectiveness was seen between older and younger patients.
- Patients 65 years of age and older experienced higher rates of severe and serious side effects compared with younger patients, so closer monitoring is reasonable in this group.
Pediatrics
- Pirtobrutinib is not authorized for use in patients under 18 years of age, as no data are available to Health Canada for this population.
Dosage & Administration
- The recommended dose is 200 mg taken orally once daily, continued until the disease progresses or side effects become unacceptable.
- The tablet should be swallowed whole with water and not chewed, crushed, or split; it can be taken with or without food, at approximately the same time each day.
- Dose reductions are used to manage side effects: treatment is paused until recovery and then generally restarted at a lower dose, stepping down from 200 mg through 100 mg and 50 mg once daily depending on how many times a significant reaction has occurred, with permanent discontinuation after a fourth significant event.
- No dose adjustment is needed for mild or moderate kidney impairment, or for any degree of liver impairment.
- For severe kidney impairment, the dose should be reduced, typically to 100 mg once daily if the current dose is 200 mg, with close monitoring for toxicity; treatment should be stopped if the dose is already at 50 mg once daily.
- If a dose is missed by more than 12 hours, skip it and take the next dose at the regular scheduled time; do not take an extra dose.
- If vomiting occurs after a dose, do not take a replacement dose; continue with the next scheduled dose.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- The product monograph does not describe a specific treatment for pirtobrutinib overdose; management consists of general supportive measures.
Common side effects
- Fatigue may occur.
- Musculoskeletal pain (muscle, bone, or joint pain) may occur.
- Diarrhea may occur.
- Bruising may occur.
- Cough may occur.
- Nausea may occur.
- Constipation may occur.
- Swelling (edema) may occur.
- Dizziness may occur.
- Rash may occur.
- Headache may occur.
- Decreased appetite may occur.
- Fever may occur.
- Insomnia may occur.
- Shortness of breath (dyspnea) may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Serious, and sometimes fatal, bleeding has occurred, including gastrointestinal and intracranial bleeding; the risk is higher in patients taking blood thinners or antiplatelet drugs.
- Low blood cell counts, including neutropenia, anemia, and thrombocytopenia, can become severe and require blood count monitoring.
- Serious and sometimes fatal infections, including bacterial, viral, and fungal infections, and opportunistic infections such as Pneumocystis jirovecii pneumonia, can occur.
- Second primary cancers, most often non-melanoma skin cancers, have developed in some patients; regular skin checks and sun protection are recommended.
- Heart rhythm disturbances, including atrial fibrillation, atrial flutter, and other arrhythmias, may occur; report palpitations, dizziness, fainting, or shortness of breath promptly.
- Liver injury, including rare cases of liver failure, has been reported with this class of drug.
- Tumor lysis syndrome, a rapid breakdown of cancer cells that can affect kidney function and electrolyte balance, has been reported rarely, mainly in patients with a high burden of disease before starting treatment.
- Seek urgent medical attention for unusual bleeding or bruising, black or bloody stools, sudden severe headache, chest pain, a fast or irregular heartbeat, fainting, signs of infection such as fever or chills, or yellowing of the skin or eyes.
Use with caution
- Use with caution, and monitor blood counts regularly, given the risk of low neutrophil, red blood cell, and platelet counts.
- Use with caution in patients taking anticoagulant or antiplatelet medications, given the increased risk of bleeding; discuss the risks and benefits of continuing these medications with a specialist.
- Consider stopping pirtobrutinib for 3 to 5 days before and after surgery, depending on the type of surgery and bleeding risk.
- Use with caution in patients with cardiac risk factors, such as high blood pressure or a prior history of arrhythmia, given the risk of atrial fibrillation and other rhythm disturbances.
- Use with caution in patients at risk of tumor lysis syndrome, such as those with a high burden of disease before starting treatment.
- Consider preventive measures, including vaccination and antimicrobial prophylaxis, in patients at increased risk of opportunistic infections.
- Monitor liver function before starting treatment and periodically during treatment.
- Monitor for the appearance of new skin lesions or growths, given the risk of second skin cancers.
- Treatment should be initiated and supervised only by a qualified healthcare practitioner experienced in the use of anticancer therapies.
Contraindications
- Contraindicated in patients with known hypersensitivity to pirtobrutinib or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
- Strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir, and clarithromycin, increase pirtobrutinib blood levels and may require a lower pirtobrutinib dose.
- Strong CYP3A inducers, such as rifampin and rifabutin, and moderate CYP3A inducers, such as efavirenz and bosentan, reduce pirtobrutinib blood levels and may require a higher pirtobrutinib dose.
- St. John's Wort, a strong inducer of CYP3A, should be avoided with pirtobrutinib.
- Pirtobrutinib can raise blood levels of sensitive CYP3A substrates such as midazolam, everolimus, sirolimus, and tacrolimus, increasing their effects and side effects.
- Pirtobrutinib can raise blood levels of sensitive CYP2C8 substrates such as repaglinide.
- Pirtobrutinib can raise blood levels of sensitive CYP2C19 substrates such as omeprazole.
- Pirtobrutinib can raise blood levels of P-glycoprotein substrates such as digoxin.
- Pirtobrutinib can raise blood levels of BCRP substrates such as rosuvastatin.
- Use with warfarin or other vitamin K antagonists has not been studied; weigh the risks and benefits of combining pirtobrutinib with any anticoagulant or antiplatelet therapy.
Food interactions
- Pirtobrutinib can be taken with or without food; a high-fat meal modestly lowers and delays peak blood levels but does not meaningfully change total drug exposure.
Time of administration
- Take at approximately the same time each day, with or without food.
Storage
- Store at room temperature (15°C to 30°C).
Patient take-away
- Pirtobrutinib (JAYPIRCA) is a once-daily targeted cancer therapy for certain relapsed or hard-to-treat lymphomas and leukemias that have already been treated with a BTK inhibitor.
- It carries a risk of serious bleeding, low blood cell counts, infections, and heart rhythm changes, so regular blood tests and monitoring by your cancer care team are essential.
- Tell your care team about all medications you take, including over-the-counter products and herbal supplements, since many can change pirtobrutinib levels or its effect on other drugs.
- Seek urgent care for unusual bleeding, signs of infection, a fast or irregular heartbeat, or yellowing of the skin or eyes.